Literature DB >> 33249289

Monitoring for outbreak-associated excess mortality in an African city: Detection limits in Antananarivo, Madagascar.

Fidisoa Rasambainarivo1, Anjarasoa Rasoanomenjanahary2, Joelinotahiana Hasina Rabarison3, Tanjona Ramiadantsoa4, Rila Ratovoson3, Rindra Randremanana3, Santatriniaina Randrianarisoa5, Malavika Rajeev6, Bruno Masquelier7, Jean Michel Heraud3, C Jessica E Metcalf8, Benjamin L Rice9.   

Abstract

OBJECTIVES: Quantitative estimates of the impact of infectious disease outbreaks are required to develop measured policy responses. In many low- and middle-income countries, inadequate surveillance and incompleteness of death registration are important barriers.
DESIGN: Here, we characterize how large an impact on mortality would have to be for being detectable using the uniquely detailed mortality notification data from the city of Antananarivo, Madagascar, with application to a recent measles outbreak.
RESULTS: The weekly mortality rate of children during the 2018-2019 measles outbreak was 161% above the expected value at its peak, and the signal can be detected earlier in children than in the general population. This approach to detect anomalies from expected baseline mortality allows us to delineate the prevalence of COVID-19 at which excess mortality would be detectable with the existing death notification system in Antananarivo.
CONCLUSIONS: Given current age-specific estimates of the COVID-19 fatality ratio and the age structure of the population in Antananarivo, we estimate that as few as 11 deaths per week in the 60-70 years age group (corresponding to an infection rate of approximately 1%) would detectably exceed the baseline. Data from 2020 will undergo necessary processing and quality control in the coming months. Our results provide a baseline for interpreting this information.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  COVID-19; Excess mortality; Madagascar; Measles

Mesh:

Year:  2020        PMID: 33249289     DOI: 10.1016/j.ijid.2020.11.182

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  5 in total

1.  A Statistical Analysis of Death Rates in Italy for the Years 2015-2020 and a Comparison with the Casualties Reported from the COVID-19 Pandemic.

Authors:  Gianluca Bonifazi; Luca Lista; Dario Menasce; Mauro Mezzetto; Alberto Oliva; Daniele Pedrini; Roberto Spighi; Antonio Zoccoli
Journal:  Infect Dis Rep       Date:  2021-04-01

2.  Comparing transmission potential networks based on social network surveys, close contacts and environmental overlap in rural Madagascar.

Authors:  Kayla Kauffman; Courtney S Werner; Georgia Titcomb; Michelle Pender; Jean Yves Rabezara; James P Herrera; Julie Teresa Shapiro; Alma Solis; Voahangy Soarimalala; Pablo Tortosa; Randall Kramer; James Moody; Peter J Mucha; Charles Nunn
Journal:  J R Soc Interface       Date:  2022-01-12       Impact factor: 4.118

3.  Existing human mobility data sources poorly predicted the spatial spread of SARS-CoV-2 in Madagascar.

Authors:  Tanjona Ramiadantsoa; C Jessica E Metcalf; Antso Hasina Raherinandrasana; Santatra Randrianarisoa; Benjamin L Rice; Amy Wesolowski; Fidiniaina Mamy Randriatsarafara; Fidisoa Rasambainarivo
Journal:  Epidemics       Date:  2021-12-03       Impact factor: 5.324

4.  Prioritizing COVID-19 vaccination efforts and dose allocation within Madagascar.

Authors:  Fidisoa Rasambainarivo; Tanjona Ramiadantsoa; Antso Raherinandrasana; Santatra Randrianarisoa; Benjamin L Rice; Michelle V Evans; Benjamin Roche; Fidiniaina Mamy Randriatsarafara; Amy Wesolowski; Jessica C Metcalf
Journal:  BMC Public Health       Date:  2022-04-12       Impact factor: 4.135

5.  Existing human mobility data sources poorly predicted the spatial spread of SARS-CoV-2 in Madagascar.

Authors:  Tanjona Ramiadantsoa; C Jessica E Metcalf; Antso Hasina Raherinandrasana; Santatra Randrianarisoa; Benjamin L Rice; Amy Wesolowski; Fidiniaina Mamy Randriatsarafara; Fidisoa Rasambainarivo
Journal:  medRxiv       Date:  2021-08-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.